We’re all familiar with the old saying “sticks and stones may break my bones but words will never hurt me.” @mcflyharry@Konnie_Huq recount their experiences of being bullied in school and how they navigate bullying now that they have children of their own bbc.co.uk/bitesize/artic…
As a parent it can be difficult to identify bullying as it's happening. Star parents @mcflyharry@Konnie_Huq discuss their own experiences of bullying in school, how to spot the signs of #bullying & ways to approach the subject with your child @bbcbitesize bbc.co.uk/bitesize/artic…
When talking to your child ask open questions e.g. “How are you finding school? What do you like to do at break time?”, not closed questions that can only be answered with a ‘yes’ or ‘no’ e.g. “Do you have friends at school?”
Anjula Mutanda @therealanjulam
With increased longevity how do we tackle age-related disease?
How can we engage & empower patients in their healthcare journeys?
How do we increase access to breakthrough therapies for patients with rare diseases?
What's the future of AI in drug discovery lifescienceintegrates.com/agenda/pharma-…
News 1) #MeToo comes to STEM. The @NIH shared new data detailing complaints it has received in recent years, comprising of more than 300 complaints against NIH-funded scientists. Consequently 75 investigators were removed from their grants @Scatter_Cushion the-scientist.com/news-opinion/s…
Gisela Rusteholz, Mauro Mediavilla, and Luis Pires published a case study on the Impact of bullying on academic performance. A case study for the Community of Madrid, in IEB working paper 2021/01 ideas.repec.org/p/ieb/wpaper/d…
If witnesses to harassment, members of investigative committees, journal editors, and individuals at every level of the scientific community all leverage their knowledge & power to combat bullying, we can create a safer & more civil #scientific environment
“When I was shadow foreign secretary-I did hear a number of rumours that this was a pattern of behaviour within the department. I think it’s been something of an open secret within Westminster for the last few years that there is a problem"
MP @lisanandy mirror.co.uk/news/politics/…
Lord McDonald who worked in the @FCDOGovUK when @DominicRaab was appointed foreign secretary in 2019, told @MattChorley’s show that the systems in government for allowing civil servants to make complaints about ministerial behavior were not fit for purpose thetimes.co.uk/article/d16b29…
"He claimed zero tolerance for bullying, promised a government of integrity and pledged to urgently appoint an ethics adviser, yet is falling far short on every promise. @RishiSunak is not just failing to stop the rot but letting it fester." @AngelaRayner news.sky.com/story/dominic-…
Ahead of Elizabeth Holmes’ sentencing this week, prosecutors ask for 15 years hard time. In an 82-page sentencing memorandum filed last Thursday, @eholmes2003’ team petitioned US District Judge Edward Davila to limit her time in prison to 18 months or less fiercebiotech.com/medtech/ahead-…
As Elizabeth Holmes @eholmes2003 trial nears an end, here’s a brief recap of the rise and fall of blood testing startup @theranos from its peak as a Silicon Valley darling to its current status as cautionary tale turned punchline
Andrea Park @FierceBiotech fiercebiotech.com/medtech/elizab…
“I was just totally isolated. I was told that the only people I could talk to about this were my wife, my priest, and my lawyer. And I wasn’t married, I’m not religious, and my lawyers are extremely expensive.” @theranos biotech whistleblower @TylerShultz_
While the GRADUATE results are not what we hoped, we are proud to have delivered a high quality and comprehensive Alzheimer’s dataset to the field, and we look forward to sharing our learnings with the community as we continue to search for new treatments-Levi Garraway CMO @Roche
1,965 Alzheimer's disease study participants across 30 countries were randomised 1:1 to receive gantenerumab or placebo by subcutaneous injection every 2 weeks.
Phase 3 GRADUATE I & II studies did not meet their primary endpoint of slowing clinical decline
The primary endpoint for the Phase III gantenerumab study was the change from baseline on the Clinical Dementia Rating-Sum of Boxes-CDR-SB at 116 weeks. The CDR-SB measures cognitive and functional change across six areas. There were 17 secondary endpoints roche.com/media/releases…
🧵When resources are limited, the question of what knowledge is needed and when — the ‘decision gate’ analogy — becomes the principal strategic consideration in determining the priority of activities during early drug development @NatRevDrugDisc#biotech nature.com/articles/nrd11…
Evidence showing ligands & receptors to be variable and discerning instigators of signals, and translators of information, respectively, have illustrated the fallacy of assuming that the surrogate host cell is an inert vessel-Terry Kenakin @NatRevDrugDisc nature.com/articles/nrd11…
Stepping back from the rather safe HTS paradigm to discovery in virtual space which is still not yet fully developed, certainly needs courageous management decisions not only in terms of financial investments, but also in organizational evolution @Aalanine nature.com/articles/nrd10…